Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 1/2 4Phase 2 1

Status

Terminated 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Leukemia, Myeloid, Acute 34Leukemia 26Lymphoma, Non-Hodgkin 23Lymphoma 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Recurrence 19Leukemia, Lymphocytic, Chronic, B-Cell 19Myelodysplastic Syndromes 18Hematologic Neoplasms 18Melanoma 16Neoplasm Metastasis 15Lymphoma, B-Cell 14Multiple Myeloma 12Pancreatic Neoplasms 11Hodgkin Disease 11Stomach Neoplasms 10Ovarian Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Breast Neoplasms 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lymphoma, Mantle-Cell 7Lymphoma, Follicular 7Uterine Cervical Neoplasms 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 5Neoplasms, Plasma Cell 5Kidney Neoplasms 5Burkitt Lymphoma 5Myeloproliferative Disorders 4

Interventions

pembrolizumab 37Carboplatin 26Radiotherapy 23Cisplatin 19Paclitaxel 18Erlotinib Hydrochloride 18Docetaxel 15Gemcitabine 14Pemetrexed 13Etoposide 12osimertinib 11Nivolumab 11durvalumab 9atezolizumab 9Radiosurgery 8Magnetic Resonance Spectroscopy 8Cetuximab 7Specimen Handling 6Cyclophosphamide 6130-nm albumin-bound paclitaxel 6Taxes 5Immunoglobulin G 5Gefitinib 5Biopsy 5Bevacizumab 5fludarabine 4Radiation 4Ipilimumab 4Disulfides 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Lung Neoplasms × fludarabine × Clear all
NCT06237881 2026-02-18

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
15 enrolled
DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

NCT06538012 2024-10-15

BAH2472

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
1 enrolled 6 charts
BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡